artemis pharma ltd
artemis pharma ltd Company Information
Company Number
07978773
Next Accounts
Dec 2025
Directors
Shareholders
lolakhon jabbarova
Group Structure
View All
Industry
Non-specialised wholesale trade
Registered Address
suite 1, 37 panton street, london, SW1Y 4EA
Website
-artemis pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of ARTEMIS PHARMA LTD at £420.4k based on a Turnover of £1.6m and 0.27x industry multiple (adjusted for size and gross margin).
artemis pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of ARTEMIS PHARMA LTD at £19.3k based on an EBITDA of £5.8k and a 3.32x industry multiple (adjusted for size and gross margin).
artemis pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of ARTEMIS PHARMA LTD at £116.8k based on Net Assets of £44.6k and 2.62x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Artemis Pharma Ltd Overview
Artemis Pharma Ltd is a live company located in london, SW1Y 4EA with a Companies House number of 07978773. It operates in the non-specialised wholesale trade sector, SIC Code 46900. Founded in March 2012, it's largest shareholder is lolakhon jabbarova with a 100% stake. Artemis Pharma Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.6m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Artemis Pharma Ltd Health Check
Pomanda's financial health check has awarded Artemis Pharma Ltd a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 6 areas for improvement. Company Health Check FAQs
3 Strong
1 Regular
6 Weak
Size
annual sales of £1.6m, make it smaller than the average company (£15.3m)
- Artemis Pharma Ltd
£15.3m - Industry AVG
Growth
3 year (CAGR) sales growth of 204%, show it is growing at a faster rate (7.9%)
- Artemis Pharma Ltd
7.9% - Industry AVG
Production
with a gross margin of 18.1%, this company has a higher cost of product (27.4%)
- Artemis Pharma Ltd
27.4% - Industry AVG
Profitability
an operating margin of 0.4% make it less profitable than the average company (5%)
- Artemis Pharma Ltd
5% - Industry AVG
Employees
with 3 employees, this is below the industry average (37)
- Artemis Pharma Ltd
37 - Industry AVG
Pay Structure
on an average salary of £44.2k, the company has an equivalent pay structure (£44.2k)
- Artemis Pharma Ltd
£44.2k - Industry AVG
Efficiency
resulting in sales per employee of £524k, this is more efficient (£372.4k)
- Artemis Pharma Ltd
£372.4k - Industry AVG
Debtor Days
it gets paid by customers after 74 days, this is later than average (50 days)
- Artemis Pharma Ltd
50 days - Industry AVG
Creditor Days
its suppliers are paid after 79 days, this is slower than average (32 days)
- Artemis Pharma Ltd
32 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Artemis Pharma Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Artemis Pharma Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 86.4%, this is a higher level of debt than the average (45.6%)
86.4% - Artemis Pharma Ltd
45.6% - Industry AVG
ARTEMIS PHARMA LTD financials
Artemis Pharma Ltd's latest turnover from March 2024 is estimated at £1.6 million and the company has net assets of £44.6 thousand. According to their latest financial statements, we estimate that Artemis Pharma Ltd has 3 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 2,591 | 7,314 | 8,091 | |||||||||
| Other Income Or Grants | ||||||||||||
| Cost Of Sales | ||||||||||||
| Gross Profit | ||||||||||||
| Admin Expenses | ||||||||||||
| Operating Profit | ||||||||||||
| Interest Payable | ||||||||||||
| Interest Receivable | ||||||||||||
| Pre-Tax Profit | 1,101 | 4,466 | 5,157 | |||||||||
| Tax | -209 | -893 | -1,032 | |||||||||
| Profit After Tax | 892 | 3,572 | 4,125 | |||||||||
| Dividends Paid | ||||||||||||
| Retained Profit | 892 | 3,572 | 4,125 | |||||||||
| Employee Costs | ||||||||||||
| Number Of Employees | ||||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | ||||||||||||
| Intangible Assets | ||||||||||||
| Investments & Other | ||||||||||||
| Debtors (Due After 1 year) | ||||||||||||
| Total Fixed Assets | ||||||||||||
| Stock & work in progress | 237,613 | 172,953 | ||||||||||
| Trade Debtors | 321,750 | 674,013 | 277,617 | 10,844 | 191,503 | 187,937 | 49,154 | 5,731 | 5,214 | 6,764 | ||
| Group Debtors | ||||||||||||
| Misc Debtors | 4,987 | 4,748 | 4,956 | 4,443 | 3,520 | |||||||
| Cash | 229,376 | 252,050 | 310,161 | 38,210 | 7,849 | 195 | ||||||
| misc current assets | 5,266 | 5,182 | 4,503 | |||||||||
| total current assets | 326,737 | 678,761 | 282,573 | 15,288 | 195,023 | 193,203 | 472,170 | 429,506 | 359,315 | 43,941 | 13,063 | 6,959 |
| total assets | 326,737 | 678,761 | 282,573 | 15,288 | 195,023 | 193,203 | 472,170 | 429,506 | 359,315 | 43,941 | 13,063 | 6,959 |
| Bank overdraft | ||||||||||||
| Bank loan | ||||||||||||
| Trade Creditors | 282,133 | 638,511 | 265,429 | 14,619 | 193,908 | 194,512 | 161,393 | 58,255 | 16,213 | 2,353 | ||
| Group/Directors Accounts | ||||||||||||
| other short term finances | ||||||||||||
| hp & lease commitments | ||||||||||||
| other current liabilities | 477,317 | 435,613 | 207,048 | |||||||||
| total current liabilities | 282,133 | 638,511 | 265,429 | 14,619 | 193,908 | 194,512 | 477,318 | 435,614 | 368,441 | 58,255 | 16,213 | 2,353 |
| loans | ||||||||||||
| hp & lease commitments | ||||||||||||
| Accruals and Deferred Income | 498 | 230 | 253 | |||||||||
| other liabilities | ||||||||||||
| provisions | ||||||||||||
| total long term liabilities | 499 | 230 | 253 | |||||||||
| total liabilities | 282,133 | 638,511 | 265,429 | 15,118 | 194,138 | 194,765 | 477,318 | 435,614 | 368,441 | 58,255 | 16,213 | 2,353 |
| net assets | 44,604 | 40,250 | 17,144 | 170 | 885 | -1,562 | -5,147 | -6,107 | -9,126 | -14,314 | -3,150 | 4,605 |
| total shareholders funds | 44,604 | 40,250 | 17,144 | 170 | 885 | -1,562 | -5,147 | -6,107 | -9,126 | -14,314 | -3,150 | 4,605 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | ||||||||||||
| Depreciation | ||||||||||||
| Amortisation | ||||||||||||
| Tax | -209 | -893 | -1,032 | |||||||||
| Stock | -237,613 | 64,660 | 172,953 | |||||||||
| Debtors | -352,024 | 396,188 | 267,286 | -179,736 | 7,087 | 187,936 | -49,153 | 43,422 | 518 | -1,551 | 6,764 | |
| Creditors | -356,378 | 373,082 | 250,810 | -179,289 | -604 | 194,512 | -161,393 | 103,138 | 42,042 | 13,859 | 2,353 | |
| Accruals and Deferred Income | -498 | 268 | -23 | -477,064 | 41,704 | 228,565 | 207,048 | |||||
| Deferred Taxes & Provisions | ||||||||||||
| Cash flow from operations | ||||||||||||
| Investing Activities | ||||||||||||
| capital expenditure | ||||||||||||
| Change in Investments | ||||||||||||
| cash flow from investments | ||||||||||||
| Financing Activities | ||||||||||||
| Bank loans | ||||||||||||
| Group/Directors Accounts | ||||||||||||
| Other Short Term Loans | ||||||||||||
| Long term loans | ||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||
| other long term liabilities | ||||||||||||
| share issue | ||||||||||||
| interest | ||||||||||||
| cash flow from financing | 68 | -554 | 1,063 | |||||||||
| cash and cash equivalents | ||||||||||||
| cash | -229,376 | -22,674 | -58,111 | 271,952 | 30,361 | 7,654 | 195 | |||||
| overdraft | ||||||||||||
| change in cash | -229,376 | -22,674 | -58,111 | 271,952 | 30,361 | 7,654 | 195 |
artemis pharma ltd Credit Report and Business Information
Artemis Pharma Ltd Competitor Analysis
Perform a competitor analysis for artemis pharma ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in SW1Y area or any other competitors across 12 key performance metrics.
artemis pharma ltd Ownership
ARTEMIS PHARMA LTD group structure
Artemis Pharma Ltd has no subsidiary companies.
Ultimate parent company
ARTEMIS PHARMA LTD
07978773
artemis pharma ltd directors
Artemis Pharma Ltd currently has 1 director, Mr Souleymane Soumahoro serving since Jul 2019.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Souleymane Soumahoro | England | 56 years | Jul 2019 | - | Director |
P&L
March 2024turnover
1.6m
-49%
operating profit
5.8k
0%
gross margin
18.1%
-1.95%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
44.6k
+0.11%
total assets
326.7k
-0.52%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
artemis pharma ltd company details
company number
07978773
Type
Private limited with Share Capital
industry
46900 - Non-specialised wholesale trade
incorporation date
March 2012
age
13
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
-
address
suite 1, 37 panton street, london, SW1Y 4EA
Bank
-
Legal Advisor
-
artemis pharma ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to artemis pharma ltd.
artemis pharma ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ARTEMIS PHARMA LTD. This can take several minutes, an email will notify you when this has completed.
artemis pharma ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
